Please login to the form below

Not currently logged in
Email:
Password:

INC Research appoints Robert Ryan

Joins CRO's new Strategic Advisory Services unit

INC Research Robert RyanINC Research has appointed Robert Ryan as vice president of regulatory strategy, consulting and submissions within its new Strategic Advisory Services unit.

He joins the contract research organisation (CRO) from CNS and pain-focused pharmaceutical development company Levare, where he was chairman of the board.

Prior to this Ryan spent time with other CROs and biopharmaceutical companies, including Quintiles, PPD, Celtic Therapeutics and Schwarz Pharma.

In his new role at INC Ryan will be tasked with positioning INC's new Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings.

Tim Dietlin, senior vice president of global consulting and strategic alliances, said: "Robert brings a unique blend of strategic leadership skills and international regulatory expertise that speaks to biopharmaceutical companies looking for guidance along the entire continuum of the drug development life cycle.

"Our Regulatory Consulting and Submissions team has a long history of exceptional work, and we look forward to continuing this track record under Robert's leadership."

10th December 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics